Effects of testosterone deficiency and therapy on the cardiometabolic syndrome in men.

Testosterone deficiency is identified as a predictor of the onset of metabolic syndrome.

• The review synthesized findings from the NCBI library and PubMed using keywords 'metabolic syndrome; testosterone deficiency; testosterone therapy'.
• Contemporary findings in the medical literature 'strongly suggest that TD is a predictor of onset of MetS'.
• Testosterone regulates differentiation, growth and function of muscle tissue and inhibits differentiation into adipocytes and fat accumulation, thereby regulating body composition.
• Testosterone deficiency may contribute to development of adiposity and metabolic syndrome.

Long-term testosterone therapy resulted in reductions across multiple cardiometabolic parameters in men with testosterone deficiency.

• Registry studies with durations up to 11 years demonstrated reductions in waist circumference, fasting blood glucose, triglycerides, systolic and diastolic blood pressure.
• High-density lipoprotein cholesterol (HDL) was increased with long-term testosterone therapy.
• These findings were described as demonstrated 'unequivocally' by long-term data from several registry studies.
• The review notes that only 4 randomized clinical trials with a duration of three years or longer have been reported over the past 80 years, making registry and observational studies the primary source of long-term data.

Long-term testosterone therapy produces substantial and sustained weight loss in men with testosterone deficiency.

• Weight loss was described as 'substantial and sustained' based on long-term registry study data.
• Duration of therapy in registry studies extended up to 11 years.
• This finding was identified as one of five key outcomes of long-term testosterone therapy.
• Understanding long-term effects required reliance on observational and registry studies due to limited randomized clinical trial data.

Long-term testosterone therapy prevents progression from prediabetes to type 2 diabetes and may result in remission of existing type 2 diabetes.

• Prevention of progression from prediabetes to type 2 diabetes was identified as a key outcome of long-term testosterone therapy.
• Remission of type 2 diabetes was identified as a potential outcome, described as 'may result in remission of type 2 diabetes'.
• Reduction of fasting blood glucose was also identified as a separate outcome of testosterone therapy.
• These glycemic findings were derived from observational and registry studies given the limited duration of available randomized controlled trials.

Long-term testosterone therapy reduces cardiovascular events and mortality in men with testosterone deficiency.

• Reduction in cardiovascular events and mortality was listed as one of five key outcomes of long-term testosterone therapy.
• This finding was supported by long-term registry study data extending up to 11 years.
• Testosterone is described as 'a metabolic, sexual, and vascular hormone' with important functions across many tissues and organs.
• Reductions in systolic and diastolic blood pressure were among the cardiometabolic improvements observed with therapy.

The evidence base for long-term testosterone therapy effects is predominantly derived from observational and registry studies rather than randomized clinical trials.

• Only 4 randomized clinical trials with a duration of three years or longer have been reported over the past 80 years.
• The authors state that 'understanding the effects of long-term T therapy (TTh) on amelioration of MetS and its components would be attained mostly from observational and registry studies'.
• Several registry studies provided data on testosterone therapy impact on metabolic syndrome for up to 11 years.
• This is described as a narrative review synthesizing available contemporary literature.